Imvax
601 Walnut St
Suite 440 W
Philadelphia, PA 19106
Main Contact: Mr. John Furey
Business Description:
The approach is an autologous, cell-based treatment that activates the full array of patient-specific antigens, resulting in both an innate and adaptive immune response. The company’s lead program is in glioblastoma multiforme (GBM), an extremely aggressive form of brain cancer with a significant unmet need. In parallel, the company is also progressing the platform in a select number of additional solid tumors where the unmet need remains great and where initial immunotherapy approaches have often failed to provide a significant benefit.
Business Type:
Business Information:
- Established in 2015
- Privately Owned
- Member Since 2020
